Document ID: FDA-2014-N-0001-0086
Agency: fda
Document Type: Notice
Title: Science Board to the Food and Drug Administration Advisory Committee;
Notice of Meeting
Posted Date: 2014-10-08T04:00Z

[Federal Register Volume 79, Number 195 (Wednesday, October 8, 2014)]
[Notices]
[Pages 60856-60857]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-24001]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No: FDA-2014-N-0001]

Science Board to the Food and Drug Administration Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Science Board to the Food and Drug 
Administration (Science Board).
    General Function of the Committee: The Science Board provides 
advice primarily to the Commissioner of Food and Drugs and other 
appropriate officials on specific complex scientific and technical 
issues important to the FDA and its mission, including emerging issues 
within the scientific community. Additionally, the Science Board 
provides advice to the Agency on keeping pace with technical and 
scientific developments including in regulatory science, input into the 
Agency's research agenda, and advice on upgrading its scientific and 
research facilities and training opportunities. It will also provide, 
where requested, expert review of Agency sponsored intramural and 
extramural scientific research programs.
    Date and Time: The meeting will be held on Wednesday, November 19, 
2014, from approximately 8:30 a.m. to

[[Page 60857]]

5:30 p.m., and Thursday, November 20, 2014, from approximately 8:30 
a.m. to 12:45 p.m.
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 
31 Conference Center, the Great Room (Rm. 1503), Sections B and C, 
Silver Spring, Maryland 20993. For those unable to attend in person, 
the meeting will also be Web cast. The link for the Web cast is 
available at https://collaboration.fda.gov/scienceboard. Information 
regarding special accommodations due to a disability, visitor parking, 
and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading ``Resources for 
You,'' click on ``Public Meetings at the FDA White Oak Campus.'' Please 
note that visitors to the White Oak Campus must enter through Building 
1.
    Contact Person: Martha Monser, Office of the Chief Scientist, 
Office of the Commissioner, Food and Drug Administration, Bldg. 32, Rm. 
4286, 10903 New Hampshire Ave., Silver Spring, Maryland 20993, 301-796-
4627, martha.monser@fda.hhs.gov, or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A 
notice in the Federal Register about last minute modifications that 
impact a previously announced advisory committee meeting cannot always 
be published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: On November 19, 2014, the Science Board will review the 
existing nonclinical and clinical data related to the use and potential 
toxicity of anesthetics and sedation drugs in the pediatric population. 
The Science Board will be asked to make recommendations on steps the 
FDA should take to further evaluate and to mitigate the risks 
associated with the use of these drugs in the pediatric population and 
mechanisms to best communicate with the public regarding this issue.
    On November 20, 2014, the Science Board will be provided with 
progress reports from two subcommittees, the Commissioner's Fellowship 
Program Evaluation subcommittee and the Science Moving Forward 
subcommittee. The Board will be asked to support the formation of a new 
subcommittee to evaluate the Office of Regulatory Affairs' current 
investments in the Food Emergency Response Network cooperative 
agreement program and funding for state laboratories to achieve 
International Organization for Standardization accreditation. The Board 
will also be asked to support the formation of a new subcommittee to 
evaluate the Centers of Excellence in Regulatory Science and Innovation 
program. A recipient of one of the fiscal year 2013 Scientific 
Achievement Awards (selected by the Board) will provide an overview of 
the activities for which the award was given.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions pertaining to issues before the Board on November 
19, 2014, may be made to the contact person on or before Wednesday, 
November 12, 2014. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 2 p.m. on November 19, 2014. Those 
individuals interested in making formal oral presentations should 
notify the contact person and submit a brief statement of the general 
nature of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation on or before 
Tuesday, November 4, 2014. Time allotted for each presentation may be 
limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak at the 
November 19, 2014, meeting by Wednesday, November 5, 2014.
    Written submissions pertaining to issues before the Board on 
November 20, 2014, may be made to the contact person on or before 
Thursday, November 13, 2014. Oral presentations from the public will be 
scheduled between approximately 12 p.m. and 12:30 p.m. on November 20, 
2014. Those individuals interested in making formal oral presentations 
should notify the contact person and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names and addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation on or before 
Wednesday, November 5, 2014. Time allotted for each presentation may be 
limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak at the 
November 20, 2014, meeting by Thursday, November 6, 2014.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Martha Monser at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: October 2, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-24001 Filed 10-7-14; 8:45 am]
BILLING CODE 4164-01-P